Sutro Biopharma Valuation
| STRO Stock | USD 15.64 1.66 11.87% |
At this time, the company appears to be overvalued. Sutro Biopharma has a current Real Value of $7.04 per share. The regular price of the company is $15.64. Our model measures the value of Sutro Biopharma from inspecting the company fundamentals such as Shares Outstanding of 85.14 M, operating margin of (4.01) %, and Return On Equity of -18.1 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sutro Biopharma's valuation include:
Price Book 2.1114 | Enterprise Value | Enterprise Value Ebitda 0.4055 | Price Sales 1.2612 | Forward PE 10.0301 |
Overvalued
Today
Please note that Sutro Biopharma's price fluctuation is risky at this time. Calculation of the real value of Sutro Biopharma is based on 3 months time horizon. Increasing Sutro Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sutro Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sutro Stock. However, Sutro Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.64 | Real 7.04 | Target 2.69 | Hype 14.72 |
The intrinsic value of Sutro Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sutro Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sutro Biopharma helps investors to forecast how Sutro stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sutro Biopharma more accurately as focusing exclusively on Sutro Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sutro Biopharma's intrinsic value based on its ongoing forecasts of Sutro Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sutro Biopharma's closest peers.
Sutro Biopharma Cash |
|
Sutro Biopharma Total Value Analysis
Sutro Biopharma is at this time projected to have valuation of (16.69 M) with market capitalization of 79.09 M, debt of 23.15 M, and cash on hands of 225.64 M. The negative valuation of Sutro Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sutro Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(16.69 M) | 79.09 M | 23.15 M | 225.64 M |
Sutro Biopharma Investor Information
About 68.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.12. Sutro Biopharma recorded a loss per share of 2.6. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Sutro Biopharma's financial statements, Sutro Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Sutro Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sutro Biopharma has an asset utilization ratio of 16.02 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Sutro Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Sutro Biopharma Profitability Analysis
Based on the key profitability measurements obtained from Sutro Biopharma's financial statements, Sutro Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Sutro Biopharma's ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-12-31 | Previous Quarter -11.5 M | Current Value -56.9 M | Quarterly Volatility 26 M |
For Sutro Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sutro Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sutro Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sutro Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sutro Biopharma over time as well as its relative position and ranking within its peers.
Sutro Biopharma Earnings per Share Projection vs Actual
By analyzing Sutro Biopharma's earnings estimates, investors can diagnose different trends across Sutro Biopharma's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Sutro Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Sutro Biopharma Ownership Allocation
Sutro Biopharma shows a total of 85.14 Million outstanding shares. Over half of Sutro Biopharma's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sutro Biopharma Profitability Analysis
The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 274.15 M.About Sutro Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Sutro Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sutro Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Sutro Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Sutro Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sutro Biopharma. We calculate exposure to Sutro Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sutro Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 63 M | 39.4 M | |
| Pretax Profit Margin | (4.17) | (3.96) | |
| Operating Profit Margin | (4.42) | (4.20) | |
| Net Loss | (4.22) | (4.01) | |
| Gross Profit Margin | 0.80 | 0.84 |
Sutro Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 7.7 M | |
| Forward Price Earnings | 10.0301 |
Sutro Biopharma Current Valuation Indicators
Sutro Biopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sutro Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sutro Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sutro Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sutro Biopharma's worth.When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.